Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals.

Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.

Results of a phase II trial on insomnia in 120 adults were announced in 2013, finding piromelatine 20/50 mg improved sleep over 4 weeks vs placebo.

[1] Phase 1A/1B studies in 2011, showed safe dose-dependent improvement in sleep.

[6] This drug article relating to the nervous system is a stub.